365NEWSX
365NEWSX
Subscribe

Welcome

Report: Johnson & Johnson Coronavirus Vaccine Study Paused Due To Participant's Unexplained Illness - Motley Fool

Report: Johnson & Johnson Coronavirus Vaccine Study Paused Due To Participant's Unexplained Illness - Motley Fool

Report: Johnson & Johnson Coronavirus Vaccine Study Paused Due To Participant's Unexplained Illness - Motley Fool
Oct 13, 2020 31 secs

The clinical trial of Johnson & Johnson's (NYSE:JNJ) COVID-19 vaccine candidate has been paused due to an unexplained illness in a study participant, according to an article published by STAT on Monday night.

Investors and industry-watchers are on heightened alert after AstraZeneca (NYSE:AZN) had to pause in its clinical trial after a patient in the study developed an illness.

AstraZeneca's AZD1222 and Johnson & Johnson's JNJ-78436735 are both adenovirus-based vaccines, where the genetic material to express the coronavirus proteins are delivered via an adenovirus.

But Johnson & Johnson's vaccine, JNJ-78436735, only requires a single dose, while AstraZeneca's AZD1222 requires two doses to be effective.

Summarized by 365NEWSX ROBOTS

RECENT NEWS

SUBSCRIBE

Get monthly updates and free resources.

CONNECT WITH US

© Copyright 2024 365NEWSX - All RIGHTS RESERVED